Manuscript: AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis

The American Society of Gene and Cell Therapy has accepted and published a manuscript from Prescient’s Carly Jones in Molecular Therapy:

AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis

This research revealed a potential treatment for pulmonary fibrosis using targeted gene therapy to restore SERCA2a expression.

Click here to download a copy of the manuscript.
RELATED CONTENT